ACC 2023 | Ultrasensitive Troponin I Monitoring with a Transdermal Wrist Device

Over the years, early diagnosis of myocardial ischemia has ranged from 0-to-3-h protocols to abbreviated guidelines with point-of-care cardiac marker dosing. However, specific devices for this have not yet been validated.

The Sengupta P. et al. research group evaluated the feasibility of using an infrared measuring device—placed on the wrist of patients—compared with blood sampling for conventional cardiac marker dosing.

A multicenter, observational study was conducted to predict elevated circulating Troponin I (TI-us) looking to correlate these photometry data with machine learning models. Patients with angina and ECG suggestive of acute coronary syndrome (ACS) were included.

The primary training endpoint of the machine learning model was the presence of elevated troponin, correlated with both methods.

Read also: ACC 2023 | PULSE-AF.

A biochemical validation was conducted, showing an area under the curve of 0.92, with a sensitivity of 0.94 and a specificity of 0.64. In the unadjusted analysis, an elevated TI-us result in wrist measurement was associated with the presence of atherosclerotic disease (odds ratio: 3.64; p = 0.001).

Conclusions: In this prospective study of patients with ACS, the use of photometry through a device on the wrist of patients showed accuracy in predicting elevated TI-us values.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: A Novel Breakthrough In Wrist-Worn Transdermal Troponin-I-Sensor Assessment For Acute Myocardial Infarction.

Reference: Presentado por Partho Sengupta en Late Breaking Trials del ACC.23/WCC Marzo 4-6, 2023, en New Orleans.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...